PeptilotOpen the web app — 3 days free

Retatrutide

Also known as: LY3437943

Retatrutide is an investigational triple agonist of the GIP, GLP-1, and glucagon receptors that has appeared in clinical research on metabolic health and body weight. As an experimental compound it has not completed the full regulatory approval process. This entry is informational and is not a recommendation to use the compound.

At a glance

CategoryGLP-1 & Incretins
Classglp1-agonist, gip-agonist, glucagon-agonist, incretin, triple-agonist
Half-life150 hours (about 6.3 days)
Typical routesubcutaneous
Common vial strengths5 mg, 10 mg, 15 mg
StorageCommonly stored refrigerated; reconstituted solutions are typically kept cold and protected from light.

Evidence and source context

Regulatory status
Investigational. As of July 2026, retatrutide is not approved for public use and is available only through clinical research.
Evidence status
Human phase 2 publications and phase 3 topline results; safety and efficacy evaluation is ongoing.
Half-life context
The published phase 2 study describes dose-proportional pharmacokinetics and an approximate six-day half-life after subcutaneous administration. The chart is a simplified educational estimate.

Primary and official sources

  1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 TrialNew England Journal of Medicine · Primary study
  2. What to know about retatrutideEli Lilly and Company · Official status

Sources checked July 24, 2026 by the Peptilot editorial team. Independent medical review is pending; this page is educational and is not a treatment recommendation for Retatrutide.

Elimination curve

100%50%25%12.5%6.31319250days after a single dose
Simple single‑compartment elimination model ((1/2)t/t½): it ignores absorption, route, and individual variation, so treat it as a shape, not a measurement. In the Peptilot app this curve is stacked across your actual logged doses.

Full clearance milestones on the Retatrutide half-life page.

Doing the vial math? The Retatrutide reconstitution calculator converts mg to insulin-syringe units, free and without an account.

Questions, answered.

What is Retatrutide?
Retatrutide is an investigational triple agonist of the GIP, GLP-1, and glucagon receptors that has appeared in clinical research on metabolic health and body weight. As an experimental compound it has not completed the full regulatory approval process. This entry is informational and is not a recommendation to use the compound.
What is Retatrutide's half-life?
Retatrutide's elimination half-life is approximately 150 hours (about 6.3 days), per published pharmacokinetic data. After about five half-lives (~750 hours (about 31 days)), a single dose is roughly 97% eliminated. Individual clearance varies.
Is Retatrutide the same as LY3437943?
LY3437943 is a brand-name medicine whose active ingredient is retatrutide. People commonly track their prescribed brand under the retatrutide entry.
What do people log alongside Retatrutide?
People tracking this investigational compound often log gastrointestinal tolerance, appetite, heart rate, and body weight over time. Peptilot has one-tap logging for doses, side effects, weight, and injection sites, so patterns show up in your own record.

Educational information for people who track their protocols — not medical advice, and never a recommendation to use any compound. Always work with a qualified healthcare provider.

Track Retatrutide with one-tap dose logs, estimated level charts, site rotation, and reminders — free for your first 3 days.

Open the web app — 3 days freeLearn more about Peptilot